CAR-NK-CD19 Cells is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase I drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAR-NK-CD19 Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAR-NK-CD19 Cells overview
CAR-NK-CD19 Cells are under development for the treatment of relapsed or refractory CD19 positive B-cell hematological malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma. The therapeutic candidate comprises cord blood derived NK cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing CD19.
Shanghai Simnova Biotechnology overview
Shanghai Simnova Biotechnology is a clinical cell therapy platform company. It is headquartered in Shanghai, China.
For a complete picture of CAR-NK-CD19 Cells’s drug-specific PTSR and LoA scores, buy the report here.